高级搜索
冯青燕, 徐金升, 白亚玲. 抗血管生成靶向药物相关性肾脏损伤的研究进展[J]. 肿瘤防治研究, 2021, 48(4): 424-428. DOI: 10.3971/j.issn.1000-8578.2021.20.0807
引用本文: 冯青燕, 徐金升, 白亚玲. 抗血管生成靶向药物相关性肾脏损伤的研究进展[J]. 肿瘤防治研究, 2021, 48(4): 424-428. DOI: 10.3971/j.issn.1000-8578.2021.20.0807
FENG Qingyan, XU Jinsheng, BAI Yaling. Progress of Antiangiogenic Drug-induced Renal Injury[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 424-428. DOI: 10.3971/j.issn.1000-8578.2021.20.0807
Citation: FENG Qingyan, XU Jinsheng, BAI Yaling. Progress of Antiangiogenic Drug-induced Renal Injury[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 424-428. DOI: 10.3971/j.issn.1000-8578.2021.20.0807

抗血管生成靶向药物相关性肾脏损伤的研究进展

Progress of Antiangiogenic Drug-induced Renal Injury

  • 摘要: 随着精准靶向治疗的不断发展,抗血管生成靶向药物在治疗晚期癌症方面取得了良好的治疗效果,但在使用过程中常常发生肾脏损伤等不良反应,降低患者的生存质量。本文主要就抗血管生成靶向药物导致肾脏损伤的机制及肾脏损伤与预后潜在关系进行综述。

     

    Abstract: With the continuous development of precision targeting medicine, antiangiogenic drugs have achieved good therapeutic effects in the treatment of advanced cancer, but renal injury and other adverse reactions often occur during the use, which reduce the quality of life of patients. This article reviews the mechanism of renal injury induced by antiangiogenic drugs and the potential relation between renal injury and prognosis.

     

/

返回文章
返回